Details

Autor(en) / Beteiligte

• Chargari, Cyrus
• Pacaut, Cécile
• Le Moulec, Sylvestre
• Moriceau, Guillaume
• Moussaid, Yassine
• Rivoirard, Romain
• Dulou, Renaud
• Jacob, Julian
• Guy, Jean-Baptiste
• Bauduceau, Olivier
• Ceccaldi, Bernard
• Védrine, Lionel
• Fournel, Pierre
• Magné, Nicolas

Titel

First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy

Ist Teil von

• Anti-cancer drugs, 2013-08, Vol.24 (7), p.736-742

Ort / Verlag

England: Wolters Kluwer Health | Lippincott Williams & Wilkins

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• The folate antimetabolite pemetrexed was approved for the treatment of patients with metastatic nonsquamous non-small-cell lung carcinoma. Its activity on brain metastases makes pemetrexed attractive in combination with whole-brain radiation therapy (WBRT), but it could also potentially increase toxicity. We examined the medical records of 43 consecutive patients with brain metastases from non-small-cell lung carcinoma. Patients received pemetrexed-based chemotherapy at a dose of 500 mg/m. The median total number of pemetrexed-based chemotherapy cycles was 4 (range1–28). During the course of chemotherapy, patients received WBRT delivering 30 Gy in 10 fractions (n=34) or 20 Gy in five fractions (n=9). The median follow-up time was 30.5 weeks (range1–79 weeks). Intracranial progression was a cause of death in nine patients (20.9%). Clinical benefit of WBRT was reported in 30 patients (69.8%). The best radiological response was a complete response in eight patients (18.6%), a partial response in 16 patients (37.2%), stable disease in 11 patients (25.6%), and progression in four patients (9.3%). A stable intracranial disease until the last follow-up was observed in 26 patients (60.5%). The median estimated overall survival was 31 weeks (95% CI24–37 weeks). Most WBRT-related toxicities were low and 21 patients (48.9%) had no reported acute neurological toxicity. One patient developed unexplained encephalopathy 5 weeks after WBRT completion in the context of progressive diffuse brain metastases. The combination of pemetrexed with WBRT led to considerable clinical improvement and tumor responses in most patients. Overall neurological toxicity was rather low. A clinical trial is essential for better analysis of the potential synergistic effects of a drug with radiation and evaluation of neurological toxicity.